New Zealand markets closed

Athira Pharma, Inc. (ATHA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.6400+0.0800 (+3.13%)
At close: 04:00PM EDT
2.6000 -0.04 (-1.52%)
After hours: 04:06PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.5600
Open2.5500
Bid2.6000 x 100
Ask2.6900 x 100
Day's range2.5050 - 2.6701
52-week range1.3300 - 4.2980
Volume97,670
Avg. volume309,660
Market cap101.188M
Beta (5Y monthly)2.84
PE ratio (TTM)N/A
EPS (TTM)-3.0900
Earnings date08 Aug 2024 - 12 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.27
  • GlobeNewswire

    Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

    BOTHELL, Wash., May 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that the U.S. District Court for the Western District of Washington issued an order providing for preliminary approval of a proposed settlement of the claims asserted nominally on behalf of Athira against the individual defendants named in the previously dis

  • GlobeNewswire

    Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates

    Topline data from Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease expected in second half of 2024 Submitted Investigational New Drug application to U.S. Food and Drug Administration for ATH-1105 for the treatment of amyotrophic lateral sclerosis; On track to dose subjects in a first-in-human study in second quarter of 2024 Strong balance sheet to support innovative pipeline through key clinical inflection points BOTHELL, Wash., M

  • GlobeNewswire

    Athira Pharma to Participate in Upcoming May Conferences

    BOTHELL, Wash., May 02, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences in May. Sidoti May 2024 Virtual Investor ConferenceFormat: Company PresentationDate and Time: Wednesday, May 8, 2024, from 10:45 a.m. - 11:15 a.m. ET Location: Virtual Th